GeneMatrix Inc.

A109820

KR7109820001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/06/2024 BST			5-day change	1st Jan Change
2,540 ^KRW	-3.24%		-2.12%	-18.20%

2023	GeneMatrix Inc.(KOSDAQ:A109820) dropped from S&P Global BMI Index	CI
2021	GeneMatrix Inc.(KOSDAQ:A109820) added to S&P Global BMI Index	CI

GeneMatrix Inc.(KOSDAQ:A109820) added to S&P Global BMI Index

September 20, 2021 at 05:00 am

Latest news about GeneMatrix Inc.

GeneMatrix Inc.(KOSDAQ:A109820) dropped from S&P Global BMI Index	18/09/23	CI
GeneMatrix Inc.(KOSDAQ:A109820) added to S&P Global BMI Index	20/09/21	CI
Vaccitech Limited announced that it has received £6 million in funding from GeneMatrix Inc., Korea Investment Partners Co. Ltd.	19/12/18	CI
GeneMatrix Inc. announced that it has received KRW 6.99999647 billion in funding from Korea Investment Partners Co. Ltd.	12/12/18	CI
GeneMatrix Inc. announced that it expects to receive KRW 6.99999647 billion in funding from Korea Investment Partners Co. Ltd.	04/12/18	CI
GeneMatrix Inc. announced that it has received KRW 3.5 billion in funding	08/02/18	CI
GeneMatrix Inc. announced that it has received KRW 6.5 billion in funding	29/01/18	CI
GeneMatrix Inc. announced that it expects to receive KRW 3.5 billion in funding	28/01/18	CI
GeneMatrix Inc. announced that it expects to receive KRW 6.5 billion in funding	28/01/18	CI
GeneMatrix Inc. announced that it has received KRW 5 billion in funding from KB Investment Co., Ltd., ID Ventures, POSCO Venture Capital Co., Ltd..	26/07/15	CI
GeneMatrix Inc. announced that it expects to receive KRW 5 billion in funding from KB Investment Co., Ltd., ID Ventures, POSCO Venture Capital Co., Ltd..	23/07/15	CI
GeneMatrix Inc.'s Equity Buyback announced on January 27, 2011 has expired.	26/07/14	CI
Tranche Update on GeneMatrix Inc.'s Equity Buyback Plan announced on January 27, 2011.	24/07/14	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till July 26, 2014.	24/01/14	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till January 26, 2014	19/07/13	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till July 27, 2013	25/01/13	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till January 2013.	26/07/12	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till July 26, 2012.	26/01/12	CI

GENEMATRIX Inc. is a Korea-based company mainly engaged in biotechnology business. The Company operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENEMATRIX INC.	-18.20%	37.09M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+39.07%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research

GeneMatrix Inc.

Equities

A109820

KR7109820001

Biotechnology & Medical Research

GeneMatrix Inc.(KOSDAQ:A109820) added to S&P Global BMI Index

Latest news about GeneMatrix Inc.

Chart GeneMatrix Inc.

Company Profile

Sector Other Biotechnology & Medical Research